Acotiamide + Esomeprazole therapy was superior to either drug's monotherapy for symptomatic relief in functional dyspepsia.

A prospective observational study was conducted to compare the impact of Acotiamide plus Esomeprazole treatment versus Acotiamide or Esomeprazole monotherapy in treating the symptoms of functional dyspepsia.

For a total of six weeks, Group 1 received Acotiamide, Group 2 received Esomeprazole, and Group 3 received a combination of Acotiamide and Esomeprazole. Utilizing a symptom evaluation scale, treatment effectiveness was evaluated. Additionally, treatment-emergent adverse events, rate of resolution, and responder rate were evaluated.

Overall, 52 subjects from each group finished the trial. From baseline to six weeks, all three study groups showed statistically significant improvements in their total abdominal symptom (TAS), postprandial distress syndrome (PDS), and epigastric pain syndrome (EPS) scale.

From baseline to week 6, combination treatment (group 3) had the greatest decrease (mean differences of 5.65, 3.53, and11.07 in PDS, EPS, and TAS scores respectively). Nasopharyngitis, diarrhoea, headaches, and fever were the most frequently witnessed adverse events.

Over the course of 6 weeks, the Acotiamide-Esomeprazole combination was more effective than monotherapy in reducing the symptoms of functional dyspepsia.